Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation
|ClinicalTrials.gov Identifier: NCT01253590|
Recruitment Status : Terminated (Lack of accrual)
First Posted : December 3, 2010
Last Update Posted : March 6, 2015
|Condition or disease||Intervention/treatment|
|Post-Operative Cancer Patients Experiencing Atrial Fibrillation||Behavioral: questionnaire about the use of ECG device|
|Study Type :||Observational|
|Actual Enrollment :||5 participants|
|Official Title:||Feasibility of Remote Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation|
|Study Start Date :||December 2010|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||November 2011|
post op cancer patients experiencing atrial fibrillation
This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.
Behavioral: questionnaire about the use of ECG device
Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
- Assess the feasibility and acceptance of continuous remote cardiac monitoring [ Time Frame: 4 to 6 weeks ]In post-operative patients with respect to recurrence of post-operative atrial fibrillation upon discharge.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01253590
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Michelle Johnson, MD||Memorial Sloan Kettering Cancer Center|